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Definition 
Heart failure (HF) is an 
abnormality of cardiac 
structure or function leading to 
failure of the heart to deliver 
oxygen at a rate 
commensurate with the 
requirements of the 
metabolizing tissues, despite 
normal filling pressures (or 
only at the expense of 
increased filling pressures) 
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 
CAD=coronary artery disease; LVH=left ventricular hypertrophy. 
Risk Factors for HF 
• Coronary artery 
disease 
• Hypertension (LVH) 
• Valvular heart disease 
• Alcoholism 
• Infection (viral) 
• Diabetes 
• Congenital heart defects 
• Other: 
– Obesity 
– Age 
– Smoking 
– High or low hematocrit level 
– Obstructive Sleep Apnea 
Epidemiology of Heart Failure 
• Approximately 1–2% of the adult population in developed 
countries has HF, with the prevalence rising to ≥10% 
among persons 70 years of age or older 1  
• ―…one-year mortality of approximately 45 percent.‖ 2 
• ―Survival ranges from 80% at 2 years for patients 
rendered free of congestion to less than 50% at 6 
months for patients with refractory symptoms.‖ 3 
 
 
 
 
 
 
 
 •1 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 
 
2  Jessup M, Brozena S, Medical Progress: Heart Failure, NEJM, 348(20): 2007-18, 2003. 
3 Nohria A, et al, Medical Management of  Advanced Heart Failure, JAMA, 287(5): 628-40, 2002. 
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Types of Heart Failure 
• Systolic (or squeezing) heart failure 
– Decreased pumping function of the heart, 
• Diastolic (or relaxation) heart failure 
– The heart does not fill with blood properly 
 
Systolic dysfunction 
• The heart no longer works well in systole:  
it does not contract well. 
Most common cause is CAD and 
infarctions, with remodeling of the 
ventricular wall. 
Cardiomyopathies can also cause systolic 
dysfunction CHF. 
Diastolic dysfunction 
• Stiff, fibrotic LV muscle does not relax in 
diastole, does not fill enough. 
• The ventricle ―fights‖ against hypertension 
and against increased afterload by becoming 
―stronger‖ and the heart muscle 
hypertrophies. 
• Concentric hypertrophy, directed inwardly, 
encroaches on the LV cavity. 
• Thus, reduced end diastolic volume, reduced 
stroke volume, reduced cardiac output. 
Diastolic dysfunction over time: 
 
 
As it progresses, CAD will often develop 
and the pathology will overlap with systolic 
dysfunction. 

    HIGH OUTPUT FAILURE   
Non-cardiac circulatory overload 
• Etiology               
 -fistula / anemia / pregnancy / hyperT4  
• Pathophysiology              
• SV  
• CO at rest  
• blood volume due to xs Na/H2O 
• Symptoms/ Signs : congestion 
Approach to HF diagnostics 
I. Symptoms and signs of HF (at rest or 
during exertion)  
II. Objective signs of systolic or diastolic 
cardiac dysfunction (preferably in 
echocardiography) at rest 
III. Positive changes on treatment (in 
questionable diagnosis of HF) 
Criteria I  и II are obligatory  
Signs and Symptoms of Heart 
Failure 
– Shortness of Breath (dyspnea) 
• WHY?  
– Blood “backs up” in the pulmonary veins because 
the heart can’t keep up with the supply an fluid 
leaks into the lungs 
• SYMPTOMS 
– Dyspnea on exertion or at rest 
– Difficulty breathing when lying flat 
– Waking up short of breath 
 
 
 
                             
Signs and Symptoms of Heart 
Failure 
– Persistent Cough or Wheezing 
• WHY?  
– Fluid “backs up” in the lungs 
• SYMPTOMS 
– Coughing that produces white or pink blood-
tinged sputum 
 
 
 
                             
Signs and Symptoms of Heart 
Failure 
– Edema 
• WHY?  
– Decreased blood flow out of the weak heart 
– Blood returning to the heart from the veins 
“backs up” causing fluid to build up in tissues 
• SYMPTOMS 
– Swelling in feet, ankles, legs or abdomen 
– Weight gain 
 
 
 
                             
One of the Best Devices for 
Monitoring Heart Failure 
 
Signs and Symptoms of Heart 
Failure 
– Tiredness, fatigue 
• WHY?  
– Heart can’t pump enough blood to meet needs of 
bodies tissues 
– Body diverts blood away from less vital organs 
(muscles in limbs) and sends it to the heart and 
brain 
• SYMPTOMS 
– Constant tired feeling 
– Difficulty with everyday activities 
 
 
 
                             
Signs and Symptoms of Heart 
Failure 
– Lack of appetite/ Nausea 
• WHY?  
– The digestive system receives less blood 
causing problems with digestion 
• SYMPTOMS 
– Feeling of being full or sick to the stomach 
 
 
                             
Signs and Symptoms of Heart 
Failure 
– Confusion/ Impaired thinking 
• WHY?  
– Changing levels of substances in the blood ( 
sodium) can cause confusion 
• SYMPTOMS 
– Memory loss or feeling of disorientation 
– Relative or caregiver may notice this first 
 
                             
Signs and Symptoms of Heart 
Failure 
– Increased heart rate 
• WHY?  
– The heart beats faster to “make up for” the loss 
in pumping function 
• SYMPTOMS 
– Heart palpitations 
– May feel like the heart is racing or throbbing 
 
                             
Sinus Tachycardia 
Cardiac Output = Heart Rate x Stroke Volume   
• If SV is reduced and fixed by heart failure, 
then an increase in CO will require an 
increase in HR.   
• Always suspect HF in a patient 
with unexplained sinus 
tachycardia. 
22 
LOCATION 
 Heart failure classified according to 
location of ventricular failure  
 One ventricle may fail independently of 
another, but failure in one will impact 
on the other. 
L sided failure- pulmonary congestion 
R sided failure- peripheral congestion 
23 
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Differential diagnosis of HF 
• Dyspnoe (respiratory system diseases, anemia, obesity, 
poor physical status (detraining), central nervous system 
diseases) 
• Cough (respiratory system diseases, side effects of 
drugs) 
• Tachycardia (thyrotoxicosis, anemia, caffeine) 
• Fatigue (cancer, diabetes, anemia, poor physical status) 
• Odema  (renal diseases, malabsorption, vein 
insufficiency, lymphostasis, myxedema) 
• Hepatomegaly (liver diseases, myelogenous leukemia, 
Budd-Chiari  syndrome) 
• Pleural effusion (pleurisy inf- / meta-, connective tissue 
diseases, myxedema,  kidney diseases) 
• Ascites (meta -  Meigs syndrome, portal hypertension, 
kidney diseases, myxedema).  
Clinical features of HF 
• The difficulties of interpretation - older 
age, obesity, female 
• Evaluation of symptoms in a variety of 
situations (at rest, during exertion, in at 
night)  
Clinical features of HF 
• After confirming the diagnosis of HF 
clinical symptoms/signs can be used to 
determine the severity of heart failure 
and to evaluate the effectiveness of 
treatment. 
• But clinical symptoms should NOT be 
used for dose titration of 
neurohormonal systems blockers.  
ECG in HF 
• Normal ECG requires a re-evaluation of 
the diagnosis, especially due to LV systolic 
dysfuntion 
• Q wave – previous AMI as the cause of HF 
СН 
• Signs of cardiac chambers hypertrophy 
• Rhythm abnormalities 


Chest X-ray investigation in 
HF  
• Detection of cardiomegaly (cardiac 
enlargement, pericardial effusion) 
• Detection of pulmonary congestion  
Chest X-ray: cardiomegaly and 
pulmonary congestion 
Echocardiography 
• The method of choice for confirmation of 
cardiac dysfunction at rest 
• The main indicator of left ventricular 
systolic function - left ventricular ejection 
fraction (LVEF): distinguishing HF with 
reduced (LVEF < 40%) and preserved LV 
systolic function 
• Cause of HF – postMI scars, valvular 
abnormalities, hypertrophy, pericardial 
effusion and so on… 
Ejection Fraction (EF) : a Key 
Indicator for Diagnosing Heart Failure 
Ejection Fraction 
(EF) is the 
percentage of 
blood that is 
pumped out of the 
ventricular during 
each beat 
 
Evaluation of diastolic LV function 
Indications: 
• clinical symptoms of heart failure with 
normal ejection fraction 
• determination of prognosis in heart failure 
• non-invasive measurement of diastolic 
pressure in the left ventricle 
• diagnostics of constrictive pericarditis 
• diagnosis of restrictive cardiomyopathy 
 
 
 
Diagnostic criteria for 
diastolic dysfunction  
Diagnosis is confirmed by the presence of 
all three components:  
1. Clinical symptoms/signs of heart failure 
2. Normal or slightly reduced (45-50%) left 
ventricular ejection fraction 
3. Signs of abnormal relaxation, flexibility 
and rigidity of the LV  
 Three types of LV diastolic 
dysfunction  
норма 
Additional non-invasive methods of 
investigation in HF  
• Indications: 
– Noninformative resting echocardiography 
– Severe / refractory heart failure in ischemic 
heart disease 
• Methods: 
– Stress echocardiography  
– radionuclide investigation 
– Magnetic resonance imaging  
Measurements of lung function  
•  Performed to rule out pulmonary 
disease as a cause of dyspnea 
• Spirometry for the assessment of 
severity of COPD which often co-exists 
with HF  
Stress testing in heart failure  
Normal results of stress tests rule out 
heart failure!  
Aims of stress tests: 
– Prognostic evaluation 
– Evaluation of the functional class of HF 
– Evaluating the effectiveness of therapy 
Holter ECG monitoring 
Indications: 
• identification of arrhythmias (atrial and 
ventricular) 
• evaluation of their characteristics 
(frequency, duration) 
  
Invasive methods of 
investigation in HF  
The purpose of invasive methods of 
investigation: 
• clarification of the cause of HF 
• prognosis evaluation 
HF: lab tests 
• Complete blood test (Нв, leucocytes, 
platelets) 
• Serum electrolytes (Na, K) 
• Renal function tests 
• Glucose  
• Urine analysis 
• Liver function tests 
• Additional tests: 
– Thyroid gland function evaluation 
Biomarkers in HF 
Natriuretic peptides (B-type natriuretic peptide 
(BNP) and N-terminal pro B-type natriuretic 
peptide (NT-proBNP) 
– Diagnosis or exclusion of HF   
– Prognosis of HF   
 
Biomarkers of myocardial injury  
– Acute HF  
Natriuretic peptides Brain Natriuretic 
peptide 
• For patients presenting with acute onset or 
worsening of symptoms, the optimal 
exclusion cut-off point is < 300 pg/mL for 
NT-proBNP and < 100 pg/mL for BNP 
• For patients presenting in a non-acute 
way, the optimum exclusion cut-off point is 
< 125 pg/mL for NT-proBNP and < 35 
pg/mL for BNP.  
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 
Classification of HF 
• Stage (after Vasilenko-Strazhesko): 
I; II-А; II-B; III 
• Variant of HF: 
– With preserved LV systolic function 
– With reduced LV systolic function (EF 
<50%)  
• Functional class according to NYHA (New 
York Heart Association) I-IV  
 
HF Stages 
 (after Vasilenko- Strazhesko) 
Stage I - the initial stage the latent heart failure, marked only 
with exertion (dyspnea, palpitations, fatigue). 
Hemodynamics is normal.  
Stage II - a long standing, severe form of heart failure. Overt 
hemodynamic abnormalities are present at rest 
Substage A  – hemodynamic abnormalities are moderate and are 
present only in one (large or small) circulation circle, i.e. one 
ventricular (left or right) failure 
Substage B –  hemodynamic abnormalities are severe and are 
present throughout the cardiovascular system (manifested in the 
large AND small circulation circles), i.e. biventricular failure 
Stage III - the final, dystrophic stage with severe 
hemodynamics impairment, significant disorders of 
metabolism and irreversible changes in the structure of 
tissues and organs.  
 
NYHA Functional Classification 
 
I:   Asymptomatic - No symptoms or limitations in 
ordinary physical activity 
 
II:  Symptomatic with moderate exertion - Mild symptoms 
and slight limitation during ordinary activity 
 
III: Symptomatic with minimal exertion - Marked limitation 
in activity even during minimal activity. Comfortable 
only at rest 
 
IV: Symptomatic at rest (cardiac cripple) - Severe 
limitation. Experiences symptoms even at rest 
 
ACC-AHA Stages of HF 
 
A:  At high risk for HF but WITHOUT structural heart 
DISEASE or symptoms of HF  
 
B:  Structural heart disease but WITHOUT SYMPTOMS 
of HF 
 
C:  Structural heart disease with prior or current 
symptoms of HF 
 
D:  Refractory HF requiring specialized interventions 
Lifestyle Changes  
 
•Eat a low-sodium, low-
fat diet 
•Lose weight 
•Stay physically active 
•Reduce or eliminate 
alcohol and caffeine 
•Quit Smoking 
What          Why 
•Sodium is bad for high blood 
pressure, causes fluid retention 
•Extra weight can put a strain 
on the heart 
•Exercise can help reduce stress 
and blood pressure 
•Alcohol and caffeine can weaken an 
already damaged heart 
•Smoking can damage blood vessels 
and make the heart beat faster 
Heart Failure Treatments: 
Medication Types 
•ACE inhibitor   
(angiotensin-converting 
enzyme)  
•ARB (angiotensin receptor 
blockers) 
•Beta-blocker 
•Digoxin 
•Diuretic 
 
•Aldosterone 
blockade 
Type     What it does 
•Expands blood vessels which lowers 
blood pressure, neurohormonal 
blockade 
•Similar to ACE inhibitor—lowers 
blood pressure 
•Reduces the action of stress 
hormones and slows the heart rate 
•Slows the heart rate and improves the 
heart’s pumping function (EF) 
•Filters sodium and excess fluid from the 
blood to reduce the heart’s workload 
•Blocks neurohormal activation and controls 
volume 
Doses of Drugs Commonly Used for HF  
Drug Initial Daily Dose(s) Maximum Doses(s) 
Mean Doses Achieved in 
Clinical Trials 
ACE Inhibitors 
Captopril 6.25 mg 3 times 50 mg 3 times 122.7 mg/d (421) 
Enalapril 2.5 mg twice 10 to 20 mg twice 16.6 mg/d (412) 
Fosinopril 5 to 10 mg once 40 mg once --------- 
Lisinopril 2.5 to 5 mg once 20 to 40 mg once 32.5 to 35.0 mg/d (444) 
Perindopril 2 mg once 8 to 16 mg once --------- 
Quinapril 5 mg twice 20 mg twice --------- 
Ramipril 1.25 to 2.5 mg once 10 mg once --------- 
Trandolapril 1 mg once 4 mg once --------- 
ARBs 
Candesartan 4 to 8 mg once 32 mg once 24 mg/d (419) 
Losartan 25 to 50 mg once 50 to 150 mg once 129 mg/d (420) 
Valsartan 20 to 40 mg twice 160 mg twice 254 mg/d (109) 
Aldosterone Antagonists 
Spironolactone 12.5 to 25 mg once 25 mg once or twice 26 mg/d (424) 
Eplerenone 25 mg once 50 mg once 42.6 mg/d (445) 
Drug Initial Daily Dose(s) Maximum Doses(s) 
Mean Doses Achieved in Clinical 
Trials 
Beta Blockers 
Bisoprolol 1.25 mg once 10 mg once 8.6 mg/d (118) 
Carvedilol 3.125 mg twice 50 mg twice 37 mg/d (446) 
Carvedilol CR 10 mg once 80 mg once --------- 
Metoprolol succinate 
extended release 
(metoprolol CR/XL) 
12.5 to 25 mg once 200 mg once 159 mg/d (447) 
Hydralazine & Isosorbide Dinitrate 
Fixed dose combination 
37.5 mg hydralazine/ 
20 mg isosorbide 
dinitrate 3 times daily 
75 mg hydralazine/ 
40  mg isosorbide 
dinitrate 3 times daily 
~175 mg hydralazine/90 mg 
isosorbide dinitrate daily 
Hydralazine and 
isosorbide dinitrate  
Hydralazine: 25 to 50 
mg, 3 or 4 times daily 
and isorsorbide 
dinitrate:  
20 to 30 mg  
3 or 4 times daily 
Hydralazine: 300 mg 
daily in divided doses 
and isosorbide dinitrate 
120 mg daily in divided 
doses 
--------- 
Doses of  Drugs Commonly Used for HF 
(cont.)  
Pharmacologic Treatment of HF 
NYHA Class I  – IV 
Treatment : 
For NYHA class II - IV patients .  
Provided  estimated creatinine  
> 30  mL / min and K +  < 5 . 0  mEq / dL 
For persistently symptomatic  
African Americans , 
NYHA class III - IV 
,  
ACEI or ARB  AND 
Beta Blocker 
,  
Loop Diuretics 
,  
Hydral - Nitrates 
,  
Aldosterone  
Antagonist 
Add Add Add 
For all volume overload ,  
NYHA class II - IV patient 
Digoxin can be beneficial in patients with HFrEF, unless contraindicated, to 
decrease hospitalizations for HF. Never proven to decrease mortality 
• Reduce HR in A Fib. 
Forth line therapy, after ACE-I, beta-blockers, diuretics.. 
Avoid in patients in sinus with diastolic dysfunction. 
 
Diuretics  
• Still best for acute symptoms of volume overload. 
Not to be used alone. Used alone, they become increasingly ineffective. 
Can be counter-productive, in decreasing volume, renal perfusion, 
activating RAA, promoting tachycardia. 
 Loop diuretics most potent.   
• Furosemide usually the first line, although HCTZ could be used. 
• Only loop diuretics are effective in renal failure. 
– Furosemide (20 – 320 mg /day),  
– Torsemide (20-200mg/day) 
 
 
 
 
 
Pharmacologic Treatment of 
HF 
 Hormonal therapies other than to correct deficiencies are 
not recommended for patients with current or prior 
symptoms of HFrEF.  
 
Drugs known to adversely affect the clinical status of 
patients with current or prior symptoms of HFrEF are 
potentially harmful and should be avoided or withdrawn 
whenever possible (e.g., most antiarrhythmic drugs, 
most calcium channel blocking drugs (except 
amlodipine), NSAIDs). 
 
Pharmacologic Treatment of 
HF 
Long-term use of infused positive inotropic drugs is potentially harmful 
for patients with HFrEF, except as palliation for patients with end-
stage disease who cannot be stabilized with standard medical 
treatment  
 
 
Calcium channel blocking drugs are not recommended as routine 
treatment for patients with HFrEF. 
 
Nutritional supplements as treatment for HF are not recommended in 
patients with current or prior symptoms of HFrEF. 
 
 
 
Pharmacologic Treatment of 
HF 
Treatment of HFpEF 
Systolic and diastolic blood pressure should be controlled according 
to published clinical practice guidelines  
Diuretics should be used for relief of symptoms due to volume 
overload 
Coronary revascularization for patients with CAD in whom angina or 
demonstrable myocardial ischemia is present despite GDMT 
(guideline- directed medical therapy) 
Management of AF according to published clinical practice guidelines 
for HFpEF to improve symptomatic HF  
Use of beta-blocking agents, ACE inhibitors, and ARBs for 
hypertension in HFpEF  
Nutritional supplementation is not recommended in HFpEF 
Rational for Medications 
(Why does my doctor have me on 
so many pills??) 
• Improve Symptoms 
– Diuretics (water pills) 
– digoxin 
• Improve Survival 
– Betablockers 
– ACE-inhibitors 
– Aldosterone blockers 
– Angiotensin receptor 
blockers (ARB’s) 
Overview of Device Therapy 61 
Biventricular Pacing 
Ventricular Dysynchrony 
• Abnormal ventricular 
conduction resulting 
in a mechanical delay 
and dysynchronous 
contraction 
BiV Pacing 
Cardiac Resynchronization 
Therapy: Indications 
– Moderate to severe CHF who have failed optimal 
medical therapy 
– EF<30% 
– Evidence of electrical conduction delay 
 
   
   
Current Indications for Implantable 
cardioverter-defibrillator (ICD) 
• Patients at high risk for 
ventricular arrhythmias 
• Patients with EF < 35% 
and NYHA class II or III 
heart failure 
• Patients with a history of 
MI and EF < 30% 
Goldberger, Z, Implantable Cardioverter-Defibrillators, JAMA,  
February 15, 2006; 295:7, pp 809 - 818 
Other Therapies? 
• Transplant 
• Artificial hearts 
 
Heart Transplantation 
• A good solution to the failing heart– get a 
new heart 
• Unfortunately we are limited by supply, not 
demand 
• Approximately 2200 transplants are 
performed yearly in the US, and this 
number  has been stable for the past 20 
years. 
Worldwide Heart Transplants  
 
Newer Generation Artificial Hearts 
 
 
